Drug information resources for health professionals and consumers.
作者信息
Durkin C
出版信息
Natl Netw. 1998 Feb;22(3):10-1.
PMID:10176590
Abstract
摘要
相似文献
1
Drug information resources for health professionals and consumers.
Natl Netw. 1998 Feb;22(3):10-1.
2
Getting SMART (submission management and review tracking) drug review in the computer age.在计算机时代实现SMART（提交管理与评审跟踪）药物评审。
FDA Consum. 1995 Oct;29(8):6-9.
3
Disease models.疾病模型。
Clin Adv Hematol Oncol. 2008 Apr;6(4):241-2.
4
The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.肿瘤药物咨询委员会纪事：第3部分。美国食品药品监督管理局评估和批准癌症药物的理念与流程。
Expert Rev Anticancer Ther. 2005 Feb;5(1):1-5. doi: 10.1586/14737140.5.1.1.
5
How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.药物基因组学将如何影响联邦政府对临床试验的监管以及新药审批流程。
Food Drug Law J. 2003;58(1):103-27.
6
The United States Food and Drug Administration and the end of antibiotics.美国食品药品监督管理局与抗生素时代的终结
Clin Infect Dis. 2002 Feb 1;34(3):420-2. doi: 10.1086/338976.
7
Maine law requires drug companies to provide clinical trial data.缅因州法律要求制药公司提供临床试验数据。
J Natl Cancer Inst. 2005 Sep 7;97(17):1246. doi: 10.1093/jnci/dji299.
8
Stoning a dead bird: advertising limits on approved new drugs.
Food Drug Law J. 1995;50(4):533-51.
9
New clinical trials policy at FDA.美国食品药品监督管理局的新临床试验政策。
Nat Biotechnol. 2006 Sep;24(9):1043. doi: 10.1038/nbt0906-1043. Epub 2006 Sep 1.
10
Trials and error.反复试验。
Nat Biotechnol. 2005 Dec;23(12):1481. doi: 10.1038/nbt1205-1481.
Zotero 插件